Monday, April 03, 2017 3:47:28 PM
Recent NVAX News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/26/2024 03:31:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2024 10:24:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2024 10:24:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/13/2024 05:13:06 PM
- Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone • PR Newswire (US) • 12/13/2024 01:00:00 PM
- Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza • PR Newswire (US) • 12/10/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2024 11:00:38 AM
- Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million • PR Newswire (US) • 12/04/2024 07:00:00 AM
- Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 11/15/2024 12:47:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2024 09:08:57 PM
- Novavax to Participate in Jefferies London Healthcare Conference • PR Newswire (US) • 11/13/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:08:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 04:21:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 01:04:48 PM
- Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights • PR Newswire (US) • 11/12/2024 01:02:00 PM
- U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial • PR Newswire (US) • 11/11/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2024 10:01:06 PM
- Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024 • PR Newswire (US) • 11/04/2024 09:30:00 PM
- Åsa Manelius Named Managing Director of Novavax AB Site • PR Newswire (US) • 11/04/2024 11:00:00 AM
- Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial • PR Newswire (US) • 10/16/2024 12:14:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 12:00:11 PM
- Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU • PR Newswire (US) • 10/09/2024 11:00:00 AM
- Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development • PR Newswire (US) • 09/25/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:08:16 PM
- Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S. • PR Newswire (US) • 09/13/2024 01:25:00 PM
The Crypto Company Highlights Blockchain Training Alliance's Successes and Momentum for 2025 • CRCW • Dec 26, 2024 8:58 AM
Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • HZLIF • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM
UAV Corp's (UMAV), Skyborne Technology to Build "SKY" Hangar at Its Costin Airport Scheduled for Groundbreaking Ceremony Winter 2025 • UMAV • Dec 20, 2024 8:30 AM